|Bid||33.50 x 100|
|Ask||34.86 x 100|
|Day's range||33.78 - 35.92|
|52-week range||13.12 - 41.60|
|PE ratio (TTM)||N/A|
|Earnings date||5 Mar 2018 - 9 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||37.21|
Intellia Therapeutics, Crispr Therapeutics and Editas Medicine are at the forefront of the new CRISPR gene editing technology, which could cure thousands of diseases.
Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. “Our collaboration with Editas is focused on utilizing our next-generation adeno-associated viral (AAV) vectors to deliver Editas’ CRISPR-based genome editing technologies to develop novel therapies for debilitating eye diseases,” said Amber Salzman, Ph.D., President and Chief Executive Officer, Adverum Biotechnologies.
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas Medicine, Inc. (NASDAQ:EDIT), Impinj, Inc. (NASDAQ:PI), Neos Therapeutics, Inc. (NASDAQ:NEOS), Nordson Corporation (NASDAQ:NDSN), National Western Life Group, Inc. (NASDAQ:NWLI), and Square, Inc. (NYSE:SQ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
In a presentation to investors on Wednesday, January 10, 2018, at 8:30 a.m. PST at the 36th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (NASDAQ:EDIT) President and CEO Katrine Bosley will discuss “EM22,” the Company’s long-range goals for the year 2022 and vision for advancing Editas Medicine as a leading genome editing company. Ms. Bosley will also outline the Company’s acquisition of certain assets and capabilities from i2 Pharmaceuticals and its affiliates (i2 Pharmaceuticals), which further expands the Company’s unparalleled gene editing platform, strengthening its guide RNA (gRNA) chemistry capabilities. This is the first acquisition by Editas Medicine.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco, CA.
Healthcare won't be the same in the future because of these pioneers in gene editing, gene sequencing, and artificial intelligence.